EA202090638A1 - ANTIBODIES AND METHODS OF APPLICATION - Google Patents

ANTIBODIES AND METHODS OF APPLICATION

Info

Publication number
EA202090638A1
EA202090638A1 EA202090638A EA202090638A EA202090638A1 EA 202090638 A1 EA202090638 A1 EA 202090638A1 EA 202090638 A EA202090638 A EA 202090638A EA 202090638 A EA202090638 A EA 202090638A EA 202090638 A1 EA202090638 A1 EA 202090638A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
methods
crtam
gist
nucleic acids
Prior art date
Application number
EA202090638A
Other languages
Russian (ru)
Inventor
Арнима Бишт
Рэйчел Дусек
Хайнин Хуан
Чак Ханнум
Джеймс Экройд
Ливия Дебан
Original Assignee
Оксфорд Биотерапьютикс Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оксфорд Биотерапьютикс Лтд filed Critical Оксфорд Биотерапьютикс Лтд
Priority claimed from PCT/GB2018/053165 external-priority patent/WO2019086878A1/en
Publication of EA202090638A1 publication Critical patent/EA202090638A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

В настоящем документе описаны антитела против CRTAM, нуклеиновые кислоты, кодирующие такие антитела, клетки-хозяева, содержащие такие нуклеиновые кислоты, кодирующие антитело, способы получения антител против CRTAM и способы лечения заболеваний, например рака человека, включая мелкоклеточный рак легкого, немелкоклеточный рак легкого (включая плоскоклеточный рак и аденокарциномы), рак кожи, включая меланому, рак молочной железы (включая TNBC), рак ободочной и прямой кишки, рак желудка, рак яичника, рак шейки матки, рак предстательной железы, рак почки, рак печени, включая гепатоцеллюлярную карциному, рак поджелудочной железы, рак головы и шеи, рак носоглотки, рак пищевода, рак мочевого пузыря и другие виды уроэпителиального рака, а также рак желудка, глиому, глиобластому, рак яичка, рак щитовидной железы, рак костей, рак желчного пузыря и желчных протоков, рак матки, рак надпочечников, саркомы, ЖКСО (GIST), нейроэндокринные опухоли и гематологические злокачественные новообразования, но не ограничиваясь указанными.This document describes antibodies against CRTAM, nucleic acids encoding such antibodies, host cells containing such nucleic acids encoding an antibody, methods for producing antibodies against CRTAM and methods of treating diseases, for example, human cancer, including small cell lung cancer, non-small cell lung cancer ( including squamous cell carcinoma and adenocarcinoma), skin cancer including melanoma, breast cancer (including TNBC), colon and rectal cancer, stomach cancer, ovarian cancer, cervical cancer, prostate cancer, kidney cancer, liver cancer including hepatocellular carcinoma , pancreatic cancer, head and neck cancer, nasopharyngeal cancer, esophageal cancer, bladder cancer and other types of uroepithelial cancer, as well as stomach cancer, glioma, glioblastoma, testicular cancer, thyroid cancer, bone cancer, gallbladder and bile duct cancer , uterine cancer, adrenal cancer, sarcomas, GIST (GIST), neuroendocrine tumors and hematological malignant neoplasms, but not limited to those indicated.

EA202090638A 2018-07-12 2018-11-01 ANTIBODIES AND METHODS OF APPLICATION EA202090638A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862697145P 2018-07-12 2018-07-12
PCT/GB2018/053165 WO2019086878A1 (en) 2017-11-02 2018-11-01 Antibodies and methods of use

Publications (1)

Publication Number Publication Date
EA202090638A1 true EA202090638A1 (en) 2020-08-18

Family

ID=72235064

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090638A EA202090638A1 (en) 2018-07-12 2018-11-01 ANTIBODIES AND METHODS OF APPLICATION

Country Status (1)

Country Link
EA (1) EA202090638A1 (en)

Similar Documents

Publication Publication Date Title
RU2509085C2 (en) Stabilised antibodies against angiopoietin-2 and their use
CY1123192T1 (en) ANTIBODIES SPECIFIC TO CLAUDIN 6 (CLDN6)
CY1119051T1 (en) ANTI-C4.4A ANTIBODIES AND THEIR USES
CY1119956T1 (en) MONOCLONIC ANTI-GT468 CANCER TREATMENTS
EA201892616A1 (en) ANTIBODIES TO PD1 AND LAG3 FOR THE TREATMENT OF MALIGNANT NUMER FORMATION
CY1125027T1 (en) MONOCLONAL ANTIBODIES AGAINST CLAUDIN-18 FOR THE TREATMENT OF CANCER
EA201790280A1 (en) ROR1- (NTRKR1) -SPECIFIC CHEMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY
CY1117437T1 (en) ANTI-MESHOTLINE ANTIBODIES AND THEIR USES
MX2019008503A (en) Chimeric antigen receptors against axl or ror2 and methods of use thereof.
UA117121C2 (en) BISPECIFIC EGFR/c-Met ANTIBODIES
RU2015115151A (en) RET INHIBITOR
EA202092735A1 (en) ANTAGONIZING CD73 ANTIBODY
EP2582727A4 (en) Antibodies to endoplasmin and their use
AR084208A1 (en) MODULATORS OF THE EFRINE A BINDING (EFNA) AND METHODS FOR USE
EA200601433A1 (en) METHODS AND COMPOSITIONS FOR TREATMENT OF TUMORS AND METASTASIS
Thöle et al. Late Cenozoic sedimentary evolution of the German North Sea–A seismic stratigraphic approach
EA201690599A1 (en) CONJUGATED ANTIBODIES AGAINST LY75 FOR CANCER TREATMENT
RU2017138468A (en) ANTIBODIES AGAINST HUMAN HER3, HAVING LOW CONTENT OF FUKOZY, AND AREAS OF THEIR APPLICATION
EA201391423A1 (en) ANTIBODIES TO ASSOCIATED ANTI-GENE 1 AND THEIR ANTIGENSIVE BINDING FRAGMENTS
EA200601405A1 (en) HUMANIZED ANTIBODY
EA201300470A1 (en) ANTIBODIES
MX2023005873A (en) Treatment of cancer.
MX2019004940A (en) Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody.
EA202090638A1 (en) ANTIBODIES AND METHODS OF APPLICATION
MX2020004431A (en) Antibodies and methods of use.